Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 147 participants.

Also called NCT07901595

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 147 participants (planned count) (from the registry)
Sponsor
Paulex Bio Inc. (from the registry)
Registry
  • NCT NCT07901595
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07901595. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2027-11-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
Condition
Healthy Volunteers and Diabetes Participants
Intervention (Drug)
PAL-119
Intervention (Drug)
Placebo
Lead sponsor
Paulex Bio Inc. (class: industry)

Record details

Record id
cardio:ct-nct07901595
Content hash
423758ebf1ef726a270a477f69ef50026db3e51ebd06ac96c3bd691f70aceab6